Methylphenidate Pharmacokinetics Properties and Therapeutic Effectiveness

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorDakwar, Amanda
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intenzív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2018-11-19T12:34:11Z
dc.date.available2018-11-19T12:34:11Z
dc.date.created2018
dc.description.abstractMethylphenidate has become the drug of choice since it is mainly prescribed for children and adults who suffer from ADHD. A psychomotor stimulant that is sold under the trade name 'Ritalin'. ADHD is one of the most common chronic childhood onset psychiatric disorders that can persist into adulthood. The effectiveness of MPH has been confirmed among children and adults who suffer from ADHD, yet the mechanism of its action is poorly understood. It is agreed by literature that these drugs produce their effects by blocking dopamine reuptake through the dopamine transporter or by inducing dopamine transporter-mediated reverse transport that causes increase in dopamine (DA) and norepinephrine (NE) concentration in central nervous system.hu_HU
dc.description.correctorSZG
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent36hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/259305
dc.language.isoenhu_HU
dc.subjectMethylphenidatehu_HU
dc.subjectADHDhu_HU
dc.subjectRitalinhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleMethylphenidate Pharmacokinetics Properties and Therapeutic Effectivenesshu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)